Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HESTIA3 ticagrelor versus placebo in pediatric sickle cell disease
PACTR201811582613213Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Ticagrelor with Placebo (2 arms). Primary endpoint: Number of vaso-occlusive crises. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR201811582613213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201811582613213.